Azacitadine May Be Safe, Effective for Older Patients with Acute Myeloid Leukemia

Share this content:

the Cancer Therapy Advisor take:

Azacitadine may be an important treatment option for older patients with newly diagnosed acute myeloid leukemia (AML) with >30% blasts, a new study published online in the journal Blood has shown.

For the multicenter, open-label, phase III trial, researchers enrolled 488 patients at least 65 years of age with newly diagnosed AML with >30% bone marrow blasts. Patients were randomly assigned 1:1 to receive azacitadine or a conventional care regimen, which included either standard induction chemotherapy, low-dose cytarabine, or supportive care only.

Results showed that median overall survival was 10.4 months (95% CI: 8.0-12.7) in the azacitadine group compared with 6.5 months (95% CI: 5.0-8.6) in the conventional care group (HR = 0.85; 95% CI: 0.69-1.03; P = 0.1009). Researchers found that the 1-year survival rates were 46.5% and 34.2% with azacitadine and conventional care regimens, respectively.

In regard to safety, adverse events were similar to those observed in previous studies with azacitadine.

FCR remains standard of care in very fit patients with chronic lymphocytic leukemia.
Azacitadine may be an important treatment option for older patients with newly diagnosed AML.
Azacitidine increased median overall survival by 3.8 months (10.4 vs 6.5 months, P=.1009) versus commonly used current AML treatments. Azacitidine safety in patients aged ≥65 years with AML (>30% blasts) was consistent with its known safety profile in other trials.
READ FULL ARTICLE From www.bloodjournal.org

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters